INO (Inovio Pharmaceuticals Inc) רווח נקי למניה (EPS TTM)

Inovio Pharmaceuticals (INO) focuses on developing innovative DNA medicines and immunotherapy methods to combat cancer and viruses, while the diversity of its product pipeline minimizes potential losses from regulatory rejections. This chart illustrates the EPS TTM dynamics, which currently stands at 69.40. The company's operations rely on its own US laboratories and the ownership of unique patents in the field of gene therapy.
INO (Inovio Pharmaceuticals, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

To assess the asset quality of Inovio Pharmaceuticals (INO), tracking real profitability dynamics is critical. Analyzing the rolling annual growth of net income per share allows for the identification of fundamental shifts in yield while excluding the impact of one-off tax factors. For a biotech firm with a unique DNA vaccine delivery platform, this metric reflects the efficiency of patent commercialization. Steady growth of this indicator would confirm the transition of potential pricing power into actual growth of shareholder equity.